ESMO Supporter 2018

Found 1 Presentation For Request ""Real-world progression-free survival of patients on anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) for ALK+ non-small cell lung cancer (NSCLC).""

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research Poster Display session

1398P - Real-World Progression-Free Survival of Patients on Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKIs) for ALK+ Non-Small Cell Lung Cancer (NSCLC)

Presentation Number
Lecture Time
12:50 - 12:50
  • Mohammad Jahanzeb (Deerfield Beach, US)
Hall A3 - Poster Area Networking Hub, ICM M√ľnchen, Munich, Germany
12:30 - 13:30



Patients with NSCLC characterized by ALK rearrangements may benefit from ALK TKI therapies. Although ALK TKIs have shown improved efficacy relative to conventional chemotherapy, the prognosis for patients with ALK+ NSCLC remains suboptimal. The present study uses real-world evidence to examine progression-free survival (PFS) among patients with ALK+ NSCLC treated with an ALK TKI.


Patients with advanced ALK+ NSCLC diagnosed and treated with an ALK TKI in 2011-2017 were identified from the Flatiron Health Electronic Health Record (EHR)-derived database. Real-world PFS (rwPFS) was estimated as the time from treatment line start to progression or death, where progression was abstracted from clinician notes and radiology/pathology reports by trained medical reviewers. Analyses examined rwPFS following the patient’s first line containing ALK TKI. For patients who received crizotinib as their first TKI followed by a second ALK TKI, a similar analysis examined rwPFS following their second ALK TKI line. Data were censored at end of follow-up for patients without progression or death. The median and 95% confidence interval (CI) of rwPFS following first and second ALK TKI were obtained from Kaplan-Meier methods.


Of 409 ALK TKI-treated patients with advanced ALK+ NSCLC, mean age was 60.4 years and 51.6% were female. Most patients (n = 379; 92.7%) received crizotinib as their first ALK TKI; of these, 180 (47.5%) were later treated with a second ALK TKI (e.g. ceritinib, alectinib). Median (95% CI) rwPFS was 7.5 (6.6-8.6) months following first ALK TKI; and 6.4 (5.2-8.2) months following second ALK TKI post-crizotinib (including 6.3 [4.3-8.4] months for ceritinib (n = 99) and 7.6 [5.2-13.6] months for alectinib (n = 64)).


In this real-world analysis of patients with advanced ALK+ NSCLC treated with earlier approved ALK TKIs, rwPFS remains short, indicating a clear need for more effective treatments of ALK+ NSCLC.

Legal entity responsible for the study

Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.


Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Editorial Acknowledgement

Writer: Beth Nordstrom; company: Evidera.


M. Jahanzeb: Research grant: Lilly, Boehringer Ingelheim, Callisto; Research grant and consultant: Ipsen, Roche/Genentech, Pfizer. H.M. Lin: Employment, stock and other ownership: Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. X. Pan, A. Desai: Employment: Takeda. B.L. Nordstrom: Employment: Evidera. All other authors have declared no conflicts of interest.